Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | CDC42 | P60953 | 1/20 | 0.51 |
| ▸ | RAC1 | P63000 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218184 | 0.83 | TDP1 (0.53) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL19719468 | 0.81 | PTGS2 (0.60) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL220447 | 0.81 | TDP1 (0.55) | TDP1L3MBTL1TSHRLMNAMAPT | |
| Naproxcinod SCHEMBL12744108 | 0.80 | TDP1 (0.54) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL1641509 | 0.80 | TDP1 (0.44) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL5605756 | 0.80 | TDP1 (0.56) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL13730523 | 0.80 | PTGS2 (0.57) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL5605758 | 0.80 | TDP1 (0.56) | TDP1L3MBTL1TSHRLMNAMAPT | |
| Naproxcinod SCHEMBL29663794 | 0.80 | PTGS2 (0.57) | TDP1L3MBTL1TSHRLMNAMAPT | |
| Naproxcinod SCHEMBL1448284 | 0.80 | PTGS2 (0.57) | TDP1L3MBTL1TSHRLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1526839-B1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX SA (FR) | 2007-03-14 | — | — | EP | claimed |
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | NICOX S.A. (FR) | 2006-08-03 | — | — | US | claimed |
| EP-1526839-A1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | Nicox S.A. (FR) | 2005-05-04 | — | — | EP | claimed |
| WO-2004000273-A1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX S.A. (FR) | 2003-12-31 | — | — | WO | claimed |
| EP-1526839-B1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX SA (FR) | 2007-03-14 | — | — | EP | disclosed |
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | NICOX S.A. (FR) | 2006-08-03 | — | — | US | disclosed |
| EP-1526839-A1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | Nicox S.A. (FR) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004000273-A1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX S.A. (FR) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | ABCG2, SLCO1B1, SLCO4C1 | TDP1 3083/4885L3MBTL1 4851/4885TSHR 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.